Endocrine Disrupting Activities of the Flavonoid Nutraceuticals Luteolin and Quercetin
- 506 Downloads
Dietary plant flavonoids have been proposed to contribute to cancer prevention, neuroprotection, and cardiovascular health through their anti-oxidant, anti-inflammatory, pro-apoptotic, and antiproliferative activities. As a consequence, flavonoid supplements are aggressively marketed by the nutraceutical industry for many purposes, including pediatric applications, despite inadequate understanding of their value and drawbacks. We show that two flavonoids, luteolin and quercetin, are promiscuous endocrine disruptors. These flavonoids display progesterone antagonist activity beneficial in a breast cancer model but deleterious in an endometrial cancer model. Concurrently, luteolin possesses potent estrogen agonist activity while quercetin is considerably less effective. These results highlight the promise and peril of flavonoid nutraceuticals and suggest caution in supplementation beyond levels attained in a healthy, plant-rich diet.
KeywordsFlavonoid Quercetin Progesterone Receptor Chronic Fatigue Syndrome Antagonist Activity
The authors thank S. Axlund for the T47D cell line containing a stably integrated CK5-luciferase reporter and for her help with the immunofluorescence experiments. M. Scully provided the Ishikawa cell line expressing estrogen receptor. We thank L. Litzenberger and S. Axlund for their assistance in the preparation of figures and K. Connaghan for guiding the statistical analysis. T.A.J. is supported by NIH/NCI R01CA125427and S.K.N by a dean’s bridge grant. University of Colorado Cancer Center Flow Cytometry and Cell Culture Shared Resources were supported by Cancer Center Support Grant (P30CA046934).
Conflict of Interest
The authors declare that they have no conflict of interest.
- 9.Wilson VS, Kathy Bobseine L, Gray Jr. E (2004) Development and characterization of a cell line that stably expresses an estrogen-responsive luciferase reporter for the detection of estrogen receptor agonist and antagonists. Toxicol Sci 81:69–77Google Scholar
- 17.Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, Manson JE, Stefanick ML, Ockene J, Sarto GE, Johnson KC, Wactawski-Wende J, Ravdin PM, Schenken R, Hendrix SL, Rajkovica A, Rohan TE, Yasmmen S, Prentice RL (2010) Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 304:1684–1692PubMedCrossRefGoogle Scholar
- 20.Zhou P, Li L-P, Luo S-Q, Jiang H-D, Zeng S (2008) Intestinal absorption of luteolin from peanut hull extract is more efficient than that from individual pure luteolin. J Agric Food Chem 56:296–300Google Scholar
- 22.Li L-P, Jiang H-D, Wu H, Zeng S (2005) Simultaneous determination of luteolin and apigenin in dog plamsa by RP-HPLC. J Pharm Biomed Anal 37:615–620Google Scholar
- 33.Verdeal K, Ryan DS (1979) Naturally-occurring estrogens in plant foodstuffs: a review. J Food Prot 42:577–583Google Scholar
- 35.Farmakalidis EJ, Hathcock JN, Murphy PA (1985) Oestrogenic potency of genistein and daidzin in mice. J Food Prot 42:577–583Google Scholar
- 37.Le Bail JC, Varnat F, Nicolas JC, Habrioux G (1998) Estrogenic and antiproliferative activities on MCF-7 human breast cancer cells by flavonoids. Cancer Lett 130:209–216Google Scholar
- 46.Mafuvadze B, Benakanakere I, López-Perez FR, Besch-Williford C, Ellersieck MR, Hyder SM (2011) Apigenin prevents development of medroxyprogesterone acetate-accelerated 7,12-dimethylbenz(a)anthracene-induced mammary tumors in Sprague–Dawley rats. Cancer Prev Res 4:1316–1324Google Scholar
- 47.Mafuvadze B, Liang Y, Besch-Williford C, Zhang X, Hyder SM (2012) Apigenin induces apoptosis and blocks growth of medroxyprogesterone acetate-dependent BT-474 xenograft tumors. Horm Cancer 3:160–171Google Scholar